<SEC-DOCUMENT>0001104659-21-024274.txt : 20210216
<SEC-HEADER>0001104659-21-024274.hdr.sgml : 20210216
<ACCEPTANCE-DATETIME>20210216164524
ACCESSION NUMBER:		0001104659-21-024274
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210211
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210216
DATE AS OF CHANGE:		20210216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		21639904

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm216961d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
February 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>BIOANALYTICAL
SYSTEMS,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in<BR>
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Indiana</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-23357</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>35-1345024</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other<BR>
jurisdiction of<BR>
incorporation or<BR>
organization)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File<BR>
Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer<BR>
        Identification No.)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2701 Kent Avenue<BR>
West Lafayette, Indiana</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>47906-1382</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(765) 463-4527</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 42.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule&nbsp;425 under
the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule&nbsp;14a-12 under
the Exchange Act (17CFR240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under
the Exchange Act (17CFR240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under
the Exchange Act (17CFR240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbols</FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Name of exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Shares</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">BASi</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">NASDAQ Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>







<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective as of February
15, 2021, the Board of Directors of Bioanalytical Systems, Inc. (the &ldquo;Company&rdquo;) elected John Gregory Beattie, age 54,
Chief Operating Officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. Beattie previously held Corporate Vice
President positions at Charles River Laboratories, a contract research organization, where he led business units within all three
of their segments.&nbsp; In these roles, Mr. Beattie was responsible for driving operational performance. There are no arrangements
or understandings between Mr. Beattie and any other persons pursuant to which he was elected as an officer and Mr. Beattie has
no family relationships with any other director or executive officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of
Mr. Beattie&rsquo;s employment, he is entitled to receive an annual base salary of $300,000 and a discretionary annual incentive
bonus which is tied to company performance metrics and individual achievements. Mr. Beattie is also entitled to participate in
the Company&rsquo;s benefit plans and programs provided to Company executives generally, subject to eligibility requirements and
the other terms and conditions of those plans and programs. On February 15, 2021, Mr. Beattie received a grant of 15,000 restricted
shares, which vest on the second anniversary of the grant date, subject to relevant vesting parameters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 11, 2021,
the Company issued a press release regarding Mr. Beattie&rsquo;s election. A copy of the press release is furnished as Exhibit
99.1 to this report. Exhibit 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 12%"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 87%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>

<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><A HREF="tm216961d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD>
    <TD>&nbsp;</TD><TD STYLE="text-align: justify"><A HREF="tm216961d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release, dated February 11, 2021.</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 42.6pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Bioanalytical Systems,&nbsp;Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: &nbsp;February 16, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Beth A. Taylor</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Beth A. Taylor</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Chief Financial Officer, Vice President &ndash; Finance</FONT></TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm216961d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="image_002.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center"><B>Bioanalytical Systems, Inc.,
doing business as Inotiv, </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center"><B>Appoints Greg Beattie as Chief
Operating Officer </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify"><B>WEST LAFAYETTE, IN</B>, February
11, 2021 -- <B>Bioanalytical Systems, Inc. (NASDAQ:BASI) (the &ldquo;Company&rdquo;, &ldquo;We&rdquo;, &ldquo;Our&rdquo; or &ldquo;Inotiv&rdquo;)</B>,
doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the appointment
of Greg Beattie as Chief Operating Officer of the Company, effective February 15, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">Mr. Beattie brings more than
30 years of contract research experience to the Company, including more than two decades in operational leadership roles at Charles
River Laboratories, where he drove growth and profitability across multiple business units. During his career at Charles River
Laboratories, Mr. Beattie held Corporate Vice President positions leading business units within all three of Charles River Laboratories&rsquo;
segments of operations (Discovery and Safety Assessment, Research Models and Services and Manufacturing Support). In these roles,
Mr. Beattie was responsible for driving operational performance for divisions with revenue in excess of $100 million. Among his
most significant accomplishments was leadership of the design, construction and staffing of one of the largest preclinical facilities
in the world in Reno, Nevada. Mr Beattie also led a new business venture (Charles River Accelerator and Development Lab), and integrated
an expanding Biologics Testing Solutions business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">Mr. Beattie holds a Bachelor
of Science degree in Biology from McGill University and a Master of Science degree in Experimental Health Sciences from Universit&eacute;
du Queb&eacute;c, and graduated from the Kellog Management Institute program at Northwestern University. Mr. Beattie held certification
as Diplomate of the American Board of Toxicology (DABT) between 1999 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">&ldquo;We continue to attract
high-caliber leaders to our team and look forward to welcoming Greg as another talented member of Inotiv,&rdquo; said Robert Leasure,
Jr., the Company's President and Chief Executive Officer. &ldquo;He is an accomplished executive with a proven industry track record,
and brings extensive experience in strategic planning, process improvement, enterprise-wide system implementation, leadership development
and team building.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">Mr. Beattie commented, &ldquo;I
am very excited to join Inotiv at this pivotal point in its growth trajectory and I look forward to helping the team drive value-creation
for our stakeholders. Inotiv has a reputation for outstanding talent, a strong client-service orientation and a winning culture,
which should provide an excellent foundation to continue to build upon.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bioanalytical Systems, Inc., doing business
as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients&rsquo; discovery and development objectives for improved decision-making
and accelerated goal attainment. The Company&rsquo;s products focus on increasing efficiency, improving data, and reducing the
cost of taking new drugs to market. Visit <U>inotivco.com</U> for more information about the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release may contain forward-looking
statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes
in the market and demand for our products and services, the development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business
and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our
operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate
other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company's filings
with the U.S. Securities and Exchange Commission.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><B>Company Contact</B></TD>
    <TD STYLE="width: 16%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 34%; text-align: justify"><B>Investor Relations</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Bioanalytical Systems, Inc., dba Inotiv</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">The Equity Group Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Beth A. Taylor, Chief Financial Officer</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Kalle Ahl, CFA</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(765) 497-8381</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(212) 836-9614</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>btaylor@inotivco.com</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><U>kahl@equityny.com</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Devin Sullivan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(212) 836-9608</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><U>dsullivan@equityny.com</U></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% (H# 2(  A$! Q$!_\0
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MV<@_3UJ7))<S=D-1;=D3T4R*6.>)98G#HPR&!X-/IIIJZ$U;1A1113 ****
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HIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  G RX# 2(  A$! Q$!_\0
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MM7T-JKSD[GMI@A$)^:97*KQVX&?2MC^VK/\ Z:_]^F_PH_MJS_Z:_P#?IO\
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MI_*S UN5I]4CFA,I!CB,&T/E\L23'C@''7=5EFU'_A)X9)[>1(V654*R!E"
M#!P._.??/M6M_;5G_P!-?^_3?X4?VU9_]-?^_3?X4?6*7\R#V-3^5F1X>>*Q
MDFC5_.@VQC[2870F0DC80<Y/O[\U'%+>QZU<S:C;3QJUG(7V2@A5!XVX[XX]
M<DFMO^VK/_IK_P!^F_PH_MJS_P"FO_?IO\*/K%+^9![&I_*S L_.EL+E=/1G
MCF=3);I*084QR S?Q-WQTJO<-=OI.F"X#QPK:DA&1I!)*,;0=I&,CIZ5T_\
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M!["I_*S0HK/_ +:LO67_ +\M_A1_;5EZR_\ ?EO\*/K%+^9!["I_*S0HK/\
M[:LO67_ORW^%']M67K+_ -^6_P */K%+^9!["I_*S0HK/_MJR]9?^_+?X4?V
MU9>LO_?EO\*/K%+^9!["I_*S0HK/_MJR]9?^_+?X4?VU9>LO_?EO\*/K%+^9
M!["I_*S0HK/_ +:LO67_ +\M_A1_;5EZR_\ ?EO\*/K%+^9!["I_*S0HK/\
M[:LO67_ORW^%']M67K+_ -^6_P */K%+^9!["I_*S0HK/_MJR]9?^_+?X4?V
MU9>LO_?EO\*/K%+^9!["I_*S0HK/_MJR]9?^_+?X4?VU9>LO_?EO\*/K%+^9
M!["I_*S0HK/_ +:LO67_ +\M_A1_;5EZR_\ ?EO\*/K%+^9!["I_*S0HHHK8
MR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
